You are here:
unknown
Behandeling van matige tot ernstige menopauze gerelateerde vasomotorische symptomen
No estimate possible yet
Registration application pending
Fezolinetant
Metabolism and Endocrinology
New medicine (specialité)
Metabolic diseases
Astellas
Receptor antagonist
Oral
Tablet
Extramural (GVS)
Neurokinine-3-receptor antagonist
Centralised (EMA)
No
September 2022
October 2023
De standaard geneesmiddelbehandeling voor vasomotorische symptomen in de menopauze is hormoontherapie met een combinatie van oestrogeen en progesteron, of oestrogeen alleen.
1 times a day
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
adisinsght
There is currently no futher information available.
Understanding of expected market entry of innovative medicines